Impax selects OmniComm's EDC solution for Phase III Parkinson's trial

OmniComm Systems, a developer of web-based electronic data capture software, has reported that Impax Pharmaceuticals, the brand division of Impax Laboratories, has selected the TrialMaster EDC solution for conducting a Phase III study in patients with Parkinson's disease.

Suneel Gupta, chief scientific officer of Impax, said: "The TrialMaster electronic data capture (EDC) solution provides us with an intuitive and easy to use export tool that simplifies the process.

"After considering multiple different EDC solutions, we selected OmniComm Systems based on its customer driven approach and reputation for delivering unparalleled service and support. Additionally, its support of industry standards has enabled us to meet our very tight corporate timelines for this important study."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: corporate, disease, export, pharmaceuticals, software, standards, trial, web